Crossmark

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients

Crossref DOI link: https://doi.org/10.1186/s40425-019-0633-x

Published Online: 2019-07-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Formenti, Silvia C.

Hawtin, Rachael E.

Dixit, Neha

Evensen, Erik

Lee, Percy

Goldberg, Judith D.

Li, Xiaochun

Vanpouille-Box, Claire

Schaue, Dörthe

McBride, William H.

Demaria, Sandra https://orcid.org/0000-0003-4426-0499
Funding

Funding for this research was provided by:

U.S. Department of Defense (W81XWH-11-1-0530, W81XWH-11-1-0531)

Breast Cancer Research Foundation

National Cancer Institute (5P30CA16087)
License Information

Text and Data Mining valid from 2019-07-11
More Information

Article History

Received: 1 March 2019

Accepted: 10 June 2019

First Online: 11 July 2019

Ethics approval and consent to participate

: All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, institutional review board approvals, and institutional safety monitoring. Written informed consent was obtained.

: Not applicable.

: The authors declare no competing financial interests related to this manuscript, but SCF has received advisory/ speaker compensation from Sanofi, Regeneron, Elekta, EMD Serono, Merck, Astra Zeneca, Bayer and research support from Varian, Bristol-Myer Squibb, Regeneron, Eisai, Merck and Janssen, and SD has received compensation for consultant/advisory services from Lytix Biopharma, AstraZeneca, Mersana Therapeutics and EMD Serono, and research support form Lytix Biopharma and Nanobiotix.